Janssen Research & Development, LLC - Recruiting 18 years or older. - A Randomized, Open-label, Multicenter, Phase 3 Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy.
Standard supportive care (packed RBC transfusion); epoetin alfa + packed RBC transfusion
Celgene Corporation - Recruiting 18 years or older. - A Phase 1a/b, Multicenter, Open Label, Dose-Finding Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the Dual DNA-PK and TOR Kinase Inhibitor, CC-115, Administered Orally to Subjects With Advanced Solid Tumors, and Hematologic Malignancies..
Medica Scientia Innovation Research - Recruiting 18 years or older. - A Phase IIa Prospective, Multicenter, Open and Not Controlled of the Efficacy and Tolerability on the First Line Treatment With Eribulin as a Unic Agent on Patients With HER2 Negative Metastatic Breast Cancer Previously Treated With Taxanes.
Hoffmann-La Roche - Recruiting 18 years to 75 years. - A Multi-center, Single-arm, Pilot Study of 5-FU Based Doublet Chemotherapy Plus Bevacizumab as Neoadjuvant Therapy for Patients With Previously Untreated Unresectable Liver-only Metastases From Colorectal Cancer.
bevacizumab [Avastin]; 5-FU based doublet chemotherapy
Centre Leon Berard - Recruiting 18 years or older. - A Phase II, Multicenter Trial Aiming to Evaluate the Clinical Interest of a Monotherapy With BKM120 , a PI3K Inhibitor in Patient With Metastatic Head and Neck Cancer Recurrent or Progressive Under Platin and Cetuximab-based Chemotherapy.
University of Maryland - Recruiting 18 years or older. - GCC 0901- A Phase II Study of Letrozole in Combination With Lapatinib Followed by an Addition of Everolimus in Postmenopausal Women With Advanced Endocrine Resistant Breast Cancer.
Catharina Ziekenhuis Eindhoven - Recruiting 18 years or older. - Phase II Multicentre Open Label Study Evaluating the Efficacy and Safety of Liposomal Doxorubicin, Trastuzumab, Docetaxel as First-line Treatment of Patients With HER2 Positive Metastatic Breast Cancer.
Non pegylated liposomal doxorubicin, trastuzumab, docetaxel
Japan Clinical Oncology Group - Recruiting 20 years to 79 years. - Randomized Phase III Trial of Postoperative Whole Brain Radiation Therapy Compared With Salvage Stereotactic Radiosurgery in Patients With One to Four Brain Metastasis: Japan Clinical Oncology Group Study (JCOG 0504).
Whole brain radiation therapy arm; Salvage stereotactic radiosurgery arm